Paula Jiménez‐Fonseca

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit	2021	Vicente Valentí Paula Jiménez‐Fonseca Pavlos Msaouel Ramón Salazar Alberto Carmona‐Bayonas
+	Bayesian interpretation of immunotherapy trials with dynamic treatment effects	2021	Eduardo Castañón Álvaro Sánchez-Arráez Paula Jiménez‐Fonseca Felipe Alvarez-Manceñido Irene Martínez‐Martínez Luka Mihic-Góngora Alberto Carmona‐Bayonas
+	Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries	2021	Alberto Carmona‐Bayonas Paula Jiménez‐Fonseca Javier Gállego Pavlos Msaouel
+ PDF Chat	Erratum to “Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings” [Eur J Cancer 136 (September 2020) 159−168]	2020	Eduardo Castañón Álvaro Sánchez-Arráez Felipe Alvarez-Manceñido Paula Jiménez‐Fonseca Alberto Carmona‐Bayonas
+	Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings	2020	Eduardo Castañón Álvaro Sánchez-Arráez Felipe Alvarez-Manceñido Paula Jiménez‐Fonseca Alberto Carmona‐Bayonas
+	Top ten errors of statistical analysis in observational studies for cancer research	2017	Alberto Carmona‐Bayonas Paula Jiménez‐Fonseca Ana Fernández‐Somoano Felipe Alvarez-Manceñido Eduardo Castañón Ana Custodio Francisco Ayala de la Peña Rubén Martín‐Payo Luís Prieto

Common Coauthors

Coauthor	Papers Together
Alberto Carmona‐Bayonas	6
Eduardo Castañón	4
Felipe Alvarez-Manceñido	4
Álvaro Sánchez-Arráez	3
Pavlos Msaouel	2
Ramón Salazar	1
Rubén Martín‐Payo	1
Francisco Ayala de la Peña	1
Ana Fernández‐Somoano	1
Irene Martínez‐Martínez	1
Luís Prieto	1
Ana Custodio	1
Javier Gállego	1
Vicente Valentí	1
Luka Mihic-Góngora	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications	2019	Rifaquat Rahman Geoffrey Fell Steffen Ventz Andrea Arfé Alyssa M. Vanderbeek Lorenzo Trippa Brian M. Alexander	2
+ PDF Chat	Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves	2012	Patricia Guyot A. E. Ades Mario JNM Ouwens Nicky J. Welton	2
+	Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects	2002	Patrick Royston Mahesh Parmar	2
+	Competing risk bias to explain the inverse relationship between smoking and malignant melanoma	2013	Caroline A. Thompson Zuo‐Feng Zhang Onyebuchi A. Arah	1
+	Quantifying the impact of survivor treatment bias in observational studies	2005	Peter C. Austin Muhammad Mamdani Carl van Walraven Jack V. Tu	1
+	A conceptual and empirical examination of justifications for dichotomization.	2009	Jamie DeCoster Anne‐Marie R. Iselin Marcello Gallucci	1
+ PDF Chat	Statistical Inference Methods for Two Crossing Survival Curves: A Comparison of Methods	2015	Huimin Li Dong Han Yawen Hou Huilin Chen Zheng Chen	1
+	Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials	2008	Duminda N. Wijeysundera Peter C. Austin Janet E. Hux W. Scott Beattie Andreas Laupacis	1
+	The Lancet's statistical review process: areas for improvement by authors	1992	S M Gore Georgina Jones Simon G. Thompson	1
+	Analyzing survival curves at a fixed point in time	2007	John P. Klein Brent R. Logan Mette Harhoff Per Kragh Andersen	1
+ PDF Chat	Common statistical and research design problems in manuscripts submitted to high-impact medical journals	2011	Sara Fernandes‐Taylor Jenny K. Hyun Rachelle Reeder Alex H. S. Harris	1
+ PDF Chat	Bayesian Statistics and the Efficiency and Ethics of Clinical Trials	2004	Donald A. Berry	1
+	Statistical reviewing policies of medical journals	1998	Steven N. Goodman Douglas G. Altman Stephen L. George	1
+	A class of rank test procedures for censored survival data	1982	David P. Harrington Thomas R. Fleming	1
+	Properties of Proportional-Hazards Score Tests under Misspecified Regression Models	1984	Stephen W. Lagakos David Schoenfeld	1
+ PDF Chat	Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines	2004	Andrea Burton Douglas G. Altman	1
+	Applied Survival Analysis: Regression Modeling of Time-to-Event Data	2008	David W. Hosmer Stanley Lemeshow Susanne May	1
+	Epidemiology: Study Design and Data Analysis	2001	Peter Callas	1
+	Bayesian dynamic regression models for interval censored survival data with application to children dental health	2013	Xiaojing Wang Ming‐Hui Chen Jun Yan	1
+ PDF Chat	Biomarkers and surrogate endpoints	2005	Jeffrey K Aronson	1
+ PDF Chat	Adjusting overall survival for treatment switches: commonly used methods and practical application	2013	Claire Watkins Xin Huang Nicholas Latimer Yiyun Tang Elaine WRIGHT	1
+	Sample size determination for the weighted log‐rank test with the Fleming–Harrington class of weights in cancer vaccine studies	2014	Takahiro Hasegawa	1
+	Multiple comparisons in interim analysis	1999	Pranab Kumar Sen	1
+	Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses	2004	Peter C. Austin Lawrence J. Brunner	1
+ PDF Chat	Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study	2015	Xabier García‐Albéniz June M. Chan Alan Paciorek Roger Logan Stacey A. Kenfield Matthew R. Cooperberg Peter R. Carroll Miguel A. Hernán	1
+ PDF Chat	An estimate of the science-wise false discovery rate and application to the top medical literature	2013	Leah R. Jager Jeffrey T. Leek	1
+ PDF Chat	On the practice of dichotomization of quantitative variables.	2002	Robert C. MacCallum Shaobo Zhang Kristopher J. Preacher Derek D. Rucker	1
+	A non-parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non-responder bias	1984	Richard Simon Robert Makuch	1
+ PDF Chat	Immortal Time Bias in Pharmacoepidemiology	2007	Samy Suissa	1
+ PDF Chat	Suspected survivor bias in case–control studies: stratify on survival time and use a negative control	2013	Nienke van Rein Suzanne C. Cannegieter Frits R. Rosendaal Pieter H. Reitsma Willem M. Lijfering	1
+	Regression Modeling Strategies	2015	Frank E. Harrell	1
+ PDF Chat	Effect of regression to the mean on decision making in health care	2003	Veronica Morton	1
+	Comparing two crossing hazard rates by Cox proportional hazards modelling	2006	Kejian Liu Peihua Qiu Jun Sheng	1
+ PDF Chat	Bias in Clinical Intervention Research	2006	Lise Lotte Gluud	1
+ PDF Chat	Crossing survival curves: alternatives to the log-rank test	2011	George Bouliotis Lucinda Billingham	1
+ PDF Chat	An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect	2014	Patrick Royston Mahesh Parmar	1
+	Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls	2002	Stuart J. Pocock Tim Clayton Douglas G. Altman	1
+ PDF Chat	Why Do Phase III Clinical Trials in Oncology Fail so Often?	2012	Laleh Amiri‐Kordestani Tito Fojo	1
+ PDF Chat	Power and sample size calculation for log‐rank test with a time lag in treatment effect	2009	Daowen Zhang Hui Quan	1
+	Multiple imputation in health‐are databases: An overview and some applications	1991	Donald B. Rubin Nathaniel Schenker	1
+ PDF Chat	Role of survivor bias in pancreatic cancer case-control studies	2015	Zhen‐Huan Hu John E. Connett Jian‐Min Yuan Kristin E. Anderson	1
+	Introduction to the Analysis of Survival Data in the Presence of Competing Risks	2016	Peter C. Austin Douglas S. Lee Jason P. Fine	1
+	Correcting treatment effect for treatment switching in randomized oncology trials with a modified iterative parametric estimation method	2016	Jin Zhang Cong Chen	1
+	Surrogate End Points and Their Validation in Oncology Clinical Trials	2016	Fengmin Zhao	1
+	Medical Statistics at a Glance	2003	Jonas F. Ludvigsson	1
+	An Analysis of the Use of Multiple Comparison Corrections in Ophthalmology Research	2012	Andrew W. Stacey Severin Pouly Craig N. Czyz	1
+	Impact of Missing Data Due to Dropouts on Estimates of the Treatment Effect in a Randomized Trial of Antiretroviral Therapy for HIV-Infected Individuals	1996	Janet Raboud Joan Montaner A. Thorne Joel Singer Martin T. Schechter	1
+	Cox Analysis of Survival Data with Non-Proportional Hazard Functions	1992	M. Schemper	1
+ PDF Chat	<b>brms</b>: An <i>R</i> Package for Bayesian Multilevel Models Using <i>Stan</i>	2017	Paul‐Christian Bürkner	1
+	Some statistical considerations in the clinical development of cancer immunotherapies	2017	Bo Huang	1